Emergent Biosolutions Inc. (NYSE:EBS) shares traded up 3.8% on Thursday . The company traded as high as $27.93 and last traded at $27.92, with a volume of 457,102 shares changing hands. The stock had previously closed at $26.90.

A number of research analysts have recently weighed in on the company. Cowen and Company restated a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a research report on Sunday, August 7th. JPMorgan Chase & Co. cut their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research report on Friday, August 5th. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. Singular Research cut their price objective on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, June 28th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Emergent Biosolutions in a research report on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $40.00.

The company has a market capitalization of $1.13 billion and a PE ratio of 20.04. The firm’s 50 day moving average is $30.18 and its 200-day moving average is $35.74.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.01. During the same quarter last year, the firm earned $0.36 EPS. The firm had revenue of $101.49 million for the quarter, compared to analyst estimates of $111.20 million. The company’s quarterly revenue was down 19.5% on a year-over-year basis. On average, analysts expect that Emergent Biosolutions Inc. will post $1.03 EPS for the current fiscal year.

In other news, Chairman Fuad El-Hibri sold 45,000 shares of Emergent Biosolutions stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $42.62, for a total value of $1,917,900.00. Following the sale, the chairman now owns 1,719,073 shares of the company’s stock, valued at $73,266,891.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 8,699 shares of Emergent Biosolutions stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $43.74, for a total transaction of $380,494.26. Following the completion of the sale, the chief executive officer now directly owns 170,966 shares in the company, valued at approximately $7,478,052.84. The disclosure for this sale can be found here.

Several hedge funds have recently modified their holdings of the stock. US Bancorp DE increased its stake in shares of Emergent Biosolutions by 6.9% in the fourth quarter. US Bancorp DE now owns 33,169 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 2,152 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Emergent Biosolutions by 6.4% in the fourth quarter. Rhumbline Advisers now owns 41,899 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 2,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Emergent Biosolutions by 24.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 50,400 shares of the biopharmaceutical company’s stock valued at $2,017,000 after buying an additional 9,900 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in shares of Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock valued at $2,317,000 after buying an additional 3,227 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Emergent Biosolutions by 5.1% in the fourth quarter. California Public Employees Retirement System now owns 104,000 shares of the biopharmaceutical company’s stock valued at $4,161,000 after buying an additional 5,000 shares during the last quarter.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.